Immunological insights into the mechanisms by which RTX is effective in Neuromyelitis Optica spectrum disorders

Documenti analoghi

• Bortezomib for neuromyelitis optica spectrum disorder: a new therapeutic option for the more severe forms? Does bortezomib inform our understanding of the immunology underlying neuromyelitis optica spectrum disorders?
  di: Taylor, J, et al.
  Pubblicazione: (2017)
• Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders
  di: Damato, V, et al.
  Pubblicazione: (2022)
• Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
  di: Kitley, J, et al.
  Pubblicazione: (2013)
• Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
  di: Kitley, J, et al.
  Pubblicazione: (2013)
• The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
  di: Nour, M, et al.
  Pubblicazione: (2014)